A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •Has received systemic small molecule therapy or radiation therapy within 28 days prior to the first dose.
• •Treatment with biologic agents including anti-PD-1 or PD-L1 antibodies for less than 6 weeks or 5 half-lives, whichever is shorter, prior to first dose.
• •Received any investigational agent less than 28 days or 5 half-lives, whichever is shorter, prior to the first dose.
• •Treatment with another IL-18 therapy.
• •Received systemic immunosuppressive agents greater than the equivalent of prednisone 10mg daily within 14 days of the study, though inhaled, intranasal, topical or intra-articular corticosteroids are allowed.
• •Certain clinically significant intercurrent disease.
• •Primary immune deficiency.
• •Active untreated brain or spine metastasis or leptomeningeal metastases.
• •Known HIV seroposivitiy, although patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents are permitted.
• •Active hepatitis A or acute or chroming hepatitis B or C infection.
• •Received a live virus vaccine within 30 days of enrollment or a COVD vaccine within 14 days.